Onkos Surgical, Inc.
$402.3K 461 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Geistlich Pharma, North America, Inc.
Geistlich Pharma, North America, Inc. reported $401,659.29 across General Payments, Research, and Ownership to 2,543 physicians and teaching hospitals across 2,560 transactions.
- $401.7K Above-median payer
- All-tracks total
- 2,560 Top quartile volume
- Transactions
- 2,543 Top quartile reach
- Recipients
- −$254.1K
- General Payments vs PY2023
Geistlich Pharma, North America, Inc. reported $401,659.29 across all CMS Open Payments tracks (General + Research + Ownership) to 2,543 physicians and teaching hospitals in Program Year 2024 - ranking #821 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $255,020.29, averaging $157.95 per recipient.
How Geistlich Pharma, North America, Inc.'s $401.7K all-tracks total breaks down
Geistlich Pharma, North America, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
31/100
Total payments
F
14/100
Transaction volume
F
29/100
Physician reach
F
29/100
Payment type diversity
D
50/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer geistlich-pharma-north-america-inc Geistlich Pharma, North America, Inc.
$401.7K · #821/1,925 · 0.0% industry · PY2024
- TOT $401.7K
- RANK #821
- SHARE 0.0%
- TXN 2,560
- RCP 2,543
- CAT 4
- GEN $255.0K
- ΔGEN −$254.1K
- TOP1 5.1%
- PY 2024
Volume peers
Nearest volume peer: Onkos Surgical, Inc. ($402.3K)
Geistlich Pharma, North America, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Geistlich Pharma, North America, Inc.'s CMS-reported General Payments decreased by $254.1K (−49.9%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: GEISTLICH PHARMA, NORTH AMERICA, INC.PY2023: GEISTLICH PHARMA, NORTH AMERICA, INC.PY2024: Geistlich Pharma, North America, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $509,160.20
- PY2024
- $255,020.29
What the Data Shows for Geistlich Pharma, North America, Inc.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Geistlich Pharma, North America, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
The 4-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Food and Beverage" at $142.6K, accounting for 55.9% of this company's General Payments and 2,442 transactions.
General Payment Breakdown by Type
"Food and Beverage" leads Geistlich Pharma, North America, Inc.'s 4-category general-payment breakdown at $142.6K, 55.9% of the reported total.
Geistlich Pharma, North America, Inc. reports 4 general-payment categories - the top three are Food and Beverage (55.9%), Travel and Lodging (29.0%), and Honoraria (11.2%). The remaining 1 category make up 3.9% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Geistlich Pharma, North America, Inc. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $142.6K | 2,442 | 55.9% |
| Travel and Lodging | $73.9K | 92 | 29.0% |
| Honoraria | $28.5K | 8 | 11.2% |
| Consulting Fee | $10.0K | 1 | 3.9% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $48,489.59 (19.0%) of $255,020.29 in this company's General Payments records across 1,635 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Geistlich Pharma, North America, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Lawrence Didomenico
$13,000.00 across 2 reported transactions
- 2
David Urbanek
$12,473.00 across 33 reported transactions
- 3
Samar Shaikh
$10,306.90 across 17 reported transactions
- 4
Michelle Butterworth
$6,621.69 across 2 reported transactions
- 5
Andrew Read-Fuller
$6,088.00 across 3 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Geistlich Pharma, North America, Inc. ranks #821 of 1,925 by total payments (top 43% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,655 of 1,838 by HHI (bottom 10% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Aerin Medical Inc. : $839.6K total payments, HHI 126
- Tricoast Surgical Solutions LLC : $83.2K total payments, HHI 126
- Prodigy Surgical Distribution, Inc. : $78.3K total payments, HHI 126
- Foundation Medical, Llc : $50.2K total payments, HHI 123
- Metacel Pharmaceuticals LLC : $1.7K total payments, HHI 123
- Immunitybio, Inc. : $67.8K total payments, HHI 122
- Geistlich Pharma, North America, Inc. (this company) : $255.0K total payments, HHI 122
- Esperion Therapeutics, Inc. : $1.3M total payments, HHI 121
- Microtransponder, Inc. : $46.1K total payments, HHI 120
- Harmony Biosciences LLC : $1.3M total payments, HHI 120
- Jazz Pharmaceuticals Inc. : $9.9M total payments, HHI 119
- Kairos Surgical Inc : $59.4K total payments, HHI 119
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Geistlich Pharma, North America, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Geistlich Pharma, North America, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Geistlich Pharma, North America, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Agfa HealthCare Corporation
$400.9K 49 recipients
Compare payment profiles
Mizuho America, Inc.
$403.0K 57 recipients
Compare payment profiles
Osseus Fusion Systems, LLC
$399.7K 120 recipients
Compare payment profiles
Nova Eye, Inc.
$404.7K 474 recipients
Compare payment profiles
Amarin Pharma Inc.
$405.1K 300 recipients
Compare payment profiles
Put this to use
Geistlich Pharma, North America, Inc. ranks #821 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just Geistlich Pharma, North America, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.